top of page
DELIVER Design and Results

Study Design

DELIVER was a randomized, double blind, placebo-controlled trial testing the hypothesis that dapagliflozin would reduce cardiovascular death or worsening heart failure in patients with heart failure and mildly reduced or preserved ejection fraction

Eligibility Criteria

To be eligible for DELIVER patients had to fulfill the following criteria:

  • Age of 40 years or older

  • NYHA Class II-IV heart failure

  • LVEF > 40% (including prior LVEF of 40% or under that had improved to over 40%)

  • Structural heart disease (LVH or LA Enlargement)

  • Elevated Natriuretic Peptides (> 300 pg/ml or 600 pg/ml if in atrial fibrillation or flutter)

  • Patients could be either ambulatory,  hospitalized or recently hospitalized

See full design details in the design manuscript

DELIVER graphic abstract.png

Primary Results


  • 6263 patients randomized and followed for a median of 2.3 years, 2 patients per group lost to follow-up

  • Dapagliflozin reduced cardiovascular death or worsening heart failure by 18% (HR 0.82, 95% CI 0.73 to 0.92, p = 0.0008)

  • Results were consistent regardless of ejection fraction, with no attenuation in patients with higher LVEF, and consistent across care setting and in all other pre-specified subgroups

See full results in primary manuscript in the New England Journal of Medicine

DELIVER graphic abstract.png
bottom of page